IPSOGEN to Undertake Pilot Study on JAK2 Cancer Biomarker with Astrazeneca
Complete the form below to unlock access to ALL audio articles.
Ipsogen has announced that it has entered into a pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research.
Under the terms of the agreement, IPSOGEN will provide AstraZeneca with JAK2-based products for initial evaluation. IPSOGEN will conduct quantitative analysis in its Marseille laboratories on samples provided by AstraZeneca. The study will help determine the viability of a test which could potentially be utilized by AstraZeneca in future clinical trials.
IPSOGEN is the exclusive worldwide licensee of the intellectual property on JAK2 V617F mutation discovered by the INSERM team of Dr. Vainchenker at Institut Gustave Roussy, Paris. IPSOGEN has developed a comprehensive solution of products and services in order to assist pharmaceutical companies in the development of JAK2 inhibitors in myeloproliferative disorders.
IPSOGEN intends to provide the best diagnostic tools in order to reduce the number of patients included into clinical trials, reduce the time to results and provide the most adapted diagnostic solution to personalize drug prescription.
“We are pleased to start up our JAK2 Pharma program with AstraZeneca a major pharmaceutical company with an outstanding vision in Personalized Medicine. We are confident that our JAK2 based diagnostic products and clinical services can satisfy Pharmaceutical companies and can improve the pace of development of therapeutic solution for cancer patients” said Vincent Fert, President and CEO of IPSOGEN.
